3 results
Approved WMOCompleted
Primary:To characterize the dose response of danirixin compared with placebo on the incidence and severity of respiratory symptoms in subjects with COPD and to compare the safety of danirixin with placebo.Secondary:To assess the annual rate of…
Approved WMORecruiting
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.
Approved WMOWill not start
Primary:To assess the efficacy of treatment with IV danirixin twice daily given with oral oseltamivir compared to oral oseltamivir twice daily on time to clinical response (TTCR)Secondary:Time to respiratory response (TTRR), clinical measures of…